This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • Oncology  • Head & Neck Cancer  • Neoplasms of Head & Neck  • Radiation Therapy  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Harold Lau, MD; Tien Phan, MD; Jack MacKinnon, MD; T. Wayne Matthews, MD

Arch Otolaryngol Head Neck Surg. 2008;134(3):257-261.

Objective  To review our institutional experience of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) and N2-N3 neck disease with respect to neck recurrence after chemoradiation without planned neck dissection (ND).

Design  Retrospective study.

Setting  Tom Baker Cancer Centre, Calgary, Alberta, Canada.

Patients  Fifty-four adults with locally advanced SCCHN and N2-N3 neck disease.

Interventions  Eighty consecutive patients were treated with chemoradiation, 70 Gy given as 2 Gy daily for 7 weeks, with cisplatin, 20 mg/m², given on the first 4 days of weeks 1 and 5. Of the 80 patients, 54 were evaluable.

Main Outcome Measures  Primary outcomes were overall survival and absence or presence of neck disease after chemoradiation. Secondary outcomes included disease-specific survival and locoregional recurrence-free survival.

Results  Median follow-up of living patients was 35 months. Patients with a complete response (CR) did not have any planned ND. Factors associated with the absence of recurrent neck disease included CR (P < .001), younger age (P = .02), and better Karnofsky Performance Status (P = .049). In patients achieving CR, 2-year overall, disease-specific, and locoregional recurrence-free survival was 92%, 95%, and 95%, respectively. Three of the 43 patients (7%) with N2 lesions obtaining CR subsequently experienced a neck recurrence at a median of 15 months (range, 7-24 months).

Conclusions  In these patients with locally advanced SCCHN and N2-N3 neck disease treated with chemoradiation and achieving CR, only a few patients with N2 neck disease experienced recurrence despite the absence of planned ND. Prospective trials are needed to identify patients with N2 neck disease who may still benefit from planned ND after chemoradiation. There were not enough patients with N3 neck disease to make any recommendations.

Author Affiliations: Department of Radiation Oncology, Tom Baker Cancer Centre (Drs Lau, Phan, and MacKinnon), and Department of Surgery, University of Calgary (Dr Matthews), Calgary, Alberta, Canada.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED LETTERS

Selecting Patients for Planned Neck Dissection After Chemoradiotherapy in Regionally Advanced Head and Neck Cancer
Jai Prakash Agarwal, Indranil Mallick, Sarbani Ghosh-Laskar, Tejpal Gupta, Ashwini Budrukkar, and Vedang Murthy
Arch Otolaryngol Head Neck Surg. 2008;134(10):1121-1122.
EXTRACT | FULL TEXT  

Selecting Patients for Planned Neck Dissection After Chemoradiotherapy in Regionally Advanced Head and Neck Cancer—Reply
Harold Lau
Arch Otolaryngol Head Neck Surg. 2008;134(10):1122.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Selecting Patients for Planned Neck Dissection After Chemoradiotherapy in Regionally Advanced Head and Neck Cancer
Agarwal et al.
Arch Otolaryngol Head Neck Surg 2008;134:1121-1122.
FULL TEXT